Deoxycytidine kinase expression in AML blasts and its relationship to leukemia-free and overall survival

• DOI: 10.1016/j.pbj.2017.07.093
• Publication Date: 2017-09-13T18:31:35Z
• Authors: L. Ng; C. Chan; T. Au; C. K. Cheng; K. F. Mo; W. Li; K. Lei; T. Mok; M. Ng; R. Raghupathy
• Keywords: Deoxycytidine kinase

Aim: Study the correlation of expression genes involved in cytarabine metabolism to leukemia-free (LFS) and overall survival (OS) AML. Introduction: Cytarabine is backbone AML therapy. Understanding roles polymorphisms resistance will facilitate development novel therapeutics. Methods: Adults less than 60 years with non M3 were included. Archived diagnostic marrow samples studied for 10 by RT-qPCR; gene normalized GAPDH was compared using unpaired t-test Welch correction. SNP rs4694362 deoxycytidine kinase (DCK) tested Taqman assay. Median time relapse calculated Kaplan Meier method. Results: 21 Han Chinese patients (median age: 50) identified; 15 male; 16 had intermediate risk cytogenetics; 5 a blast count over 100×109/L at diagnosis. 17 achieved CR; 12 after first induction. No difference seen between CR (n=12) versus (n=9) followed median duration 67.5 months; months. 1 patient who underwent allogeneic transplant CR1 excluded. Higher mean DCK LFS longer (n=7) 2 (1.91±0.67, p: 0.01) those OS (n=8) 3 (2.02±0.69, 0.01). TT genotype prevalent CT >2 year LFS; but not statistically significant. (49% vs 60%, 0.6).1,2 Conclusion: phosphorylates its active metabolite. Our work shows that higher correlated The role should be explored further Chinese.